Send us a text

Marc Elia is the Founder of M28 Capital ( https://www.m28capital.com/ ), a healthcare sector investment fund, as well as Chairman of the Board of Invivyd ( https://www.invivyd.com/ ), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, by deploying a proprietary integrated technology platform, to create best in class monoclonal antibodies.

In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates.

Marc has a passion for investing in and developing innovative healthcare solutions, and dedicated much of his career to make a meaningful difference in human health, and advocate for the development of therapies that address unmet medical needs.

Prior to M28, from January 2012 to September 2019, Marc served as a partner at Bridger Capital, an investment fund and has served on the Board of Directors of numerous companies.

Prior to his time in the healthcare investment space, Marc served in Strategy and Corporate Development roles at Chiron Corporation, in Business Development at Protein Sciences Corporation, as well as in consulting at L.E.K. Consulting.

Marc holds a B.A. in economics from Carleton College.

#MarcElia #M28Capital #Invivyd #Biopharmaceuticals #InfectiousDiseases #SARSCoV2 #MonoclonalAntibodies #Immunocompromised #RareViralEpitopes #Pemivibart #PreExposureProphylaxis #Covid19 #EmergencyUseAuthorization #EUA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

Send us a text

Dr. Bobby Reddy, MD is the Chief Operating Officer and Co-Founder of Pi Health ( https://www.pihealth.ai/ ), a health technology and clinical research company committed to empowering life sciences companies to develop medicines faster and reach diverse patient populations. Dr. Reddy leads global operations, business development, and commercial activities with the mission of driving equal access to innovative medicines and clinical trials for patients around the world.

Previously, Dr. Reddy served in leadership positions at BeiGene and AstraZeneca.

At BeiGene, Dr. Reddy was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies.

At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.

Previous to Dr. Reddy’s roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies.

Dr. Reddy is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute.

Dr. Reddy completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School.

Dr. Reddy obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School.

Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.

Important Episode Link - Pi Health Cancer Hospital -

https://www.pihealthcancerhospital.com/

#BobbyReddy #PiHealth #Dermatology #Oncology #Melanoma #Cancer #ElectronicHealthRecords #GenerativeAI #CDSCO #ClinicalTrials #India #CentralDrugsStandardControlOrganisation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #Research

Support the show

Send us a text

Dr. Mirza Rahman, MD, MPH serves as the President of the American College of Preventive Medicine ( ACPM - https://www.acpm.org/about-acpm/governance/executive-officers/mirza-rahman/ ), a professional community, founded in 1954 as a professional community for board-certified physicians to network, share their expertise and advocate for the advancement of prevention. Today, ACPM represents over 2,000 physicians, medical students, non-physicians, and other partners. All believe in the importance of preventive medicine in our society.

Dr. Rahman also serves as the Senior Vice President, Patient Safety & Pharmacovigilance at Cybin ( https://cybin.com/our-team/ ), a pharmaceutical company seeking to bring novel, second-generation psychedelics to market. He also and is a Co-Founder and President of the Guyanese Diaspora Charity ( https://www.guyanesediasporacharity.org/ ), a 501(c)(3) non-profit organization focused on helping to improve the lives of Guyanese.

In addition, Dr. Rahman is an Adjunct Associate Professor of Epidemiology at Columbia University ( https://www.publichealth.columbia.edu/profile/mirza-i-rahman-md ) and as an Adjunct Associate Professor at the University of Guyana.

Most recently, Dr. Rahman was the Vice President & Chief Safety Officer at Organon, a global healthcare company. There, he was responsible for leading and setting the broad strategic direction for pharmacovigilance for this multinational company.

Prior to that, Dr. Rahman was the Senior Vice President, Chief Global Pharmacovigilance Officer & European Research & Development Lead at Otsuka Pharmaceuticals, a global Japanese based pharmaceutical company. In 2013, he created the ACPM - Otsuka Pharmacovigilance Physician Program in Global Medical Safety.

Dr. Rahman joined Otsuka from Merck Research Laboratories, where he was an Executive Director in the Clinical Risk Management/Global Safety department. Before this, he worked at Johnson & Johnson in a variety of positions, serving as a Worldwide Vice President, Health Economics & Reimbursement at Ortho-Clinical Diagnostics in his last role there.

During his 25+ years in the pharmaceutical industry, while Dr. Rahman has worked primarily in Pharmacovigilance, he has also worked in Medical Affairs, Medical Information, Health Economics and Outcomes Research, Quality Management, Clinical Development, Manufacturing, and Regulatory Affairs.

Dr. Rahman completed his Public Health & General Preventive Medicine Residency along with his Family Medicine Residency at Stony Brook University. He completed the Advanced Management Program at the Columbia Business School and earned his Master of Public Health degree from the Columbia University School of Public Health.

Dr. Rahman earned his Doctor of Medicine degree from the Stony Brook University School of Medicine, and his Bachelor of Science degree from the Sophie Davis School of Biomedical Education at the City College of the City University of New York.

#MirzaRahman #AmericanCollegeOfPreventiveMedicine #PatientSafety #Pharmacovigilance #GuyaneseDiasporaCharity #Epidemiology #ColumbiaUniversity #UniversityOfGuyana #MedicalAffairs #HealthEconomics #OutcomesResearch #QualityManagement #ClinicalDevelopment #RegulatoryAffairs #PublicHealth #BrainHealth #DiabetesPrevention #ReducingHypertension #LifestyleMedicine #PopulationHealth #ViolencePrevention #Psychedelics #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #Research

Support the show